Thread by @haematognomist

#Medtwitter friends: I've been having a blast on the BMT service with @c_j_gibson and planning next week's #bmtsm #leusm teaching theme:

📰 Why we do what we do in allogeneic transplantation for myeloid malignancies: Classic/Pivotal trials/papers.

Any you'd add/swap out?

1⃣ Chemo vs. Auto vs. Allo in AML

Cassileth PA et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. NEJM 1998

nejm.org/doi/full/10.10…

2⃣ Donors - Related vs. Unrelated

Gupta V et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010

ashpublications.org/blood/article/…

3⃣ Stem Cell Source - PBSC vs. BM

Anasetti C et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEJM. 2012

nejm.org/doi/full/10.10…

4⃣ Conditioning Intensity - RIC vs. MAC

Scott BL et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017

pubmed.ncbi.nlm.nih.gov/28380315/

5⃣Battle of the MACs

Rambaldi A et al. BuCy vs FluBu as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015
pubmed.ncbi.nlm.nih.gov/26429297/

6⃣ Transplants in older patients?

Devine SM et al. Phase II study of allogeneic transplantation for older patients with AML in CR1 using a reduced-intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502. JCO 2015

pubmed.ncbi.nlm.nih.gov/26527780/

7⃣ Part 1: Battle of GVHD ppx regimens

Nash RA et al. A phase III study comparing Tac/MTX and cyclosporine/MTX for prophylaxis of acute graft-versus- host disease after marrow transplantation from unrelated donors. Blood 2000

pubmed.ncbi.nlm.nih.gov/10979948/

7⃣ Part 2: Battle of GVHD ppx regimens

Cutler C et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014

pubmed.ncbi.nlm.nih.gov/24982504/

@BrighamMedRes Onc friends who may find this useful @BensonMGeorge @ritikulocyte @gungulati @amin_aalipour @AminNassarMD @AmiraBarkal @ZiadBakouny @Joanneihsu @rongejman @tess_omeara @AshleyOdai @Raman @jakelee0711 @BryanCiccarelli @RyanDenu @eranhodis + Papa Heme @AaronGoodman33